Moderna, Inc. announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial...
Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024 Exclusive distribution agreement extended to also include Sweden and Denmark Alt...
Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medic...
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicit...
Alcura, a provider of specialized clinical trial services and a part of Cencora, has been granted a Manufacturing and Importation Authorization (MIA) lic...
Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high u...
Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration. Enriched IP portfoli...
Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE mark in Eu...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT...
Partnership Expands Reach of C2N’s Precivity™ Blood Tests in Over 75 Countries to Transform Alzheimer’s Disease Early Diagnosis...
Novartis is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a ground...
Calibre Scientific is pleased to announce the acquisition of ACEFE, S.A.U. (“ACEFESA” or the “Company”), a Barcelona-ba...
MSD (NYSE: MRK), known as Merck & Co., Inc. in the United States and Canada, today announced that the European Medicines Agency’s Committee for...
AbbVie announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with moderately to severely ac...
© 2025 Biopharma Boardroom. All Rights Reserved.
